Erez Chimovits bought $34.9M of Braveheart Bio (BRVE)
Executed Aug 7, disclosed Aug 11, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 11), the stock returned +5.0% (delay-adjusted); from the execution session (Aug 7), -10.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Erez Chimovits (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in ADARx Pharmaceuticals, Inc. (ADRX). Across 2 priced purchase filings, the average 21-session return was -8.1% from execution and -4.0% from disclosure (delay-adjusted; derived). The largest single filing was $34.9M of BRVE (1,940,000 sh across 2 lots, as filed), executed Aug 7.
Healthcare · Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→